Mechanisms of Tolerance and Drug Resistance

The Treatment of Epilepsy: Third Edition

Volumn , Issue , 2009, Pages 109-118

  Löscher, Wolfgang ^a   Schmidt, Dieter ^b  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^b Epilepsy Research Group   (Germany)

Author keywords

(multi)drug efflux transporters; Disease related mechanisms of drug resistance in epilepsy; Drug resistance and pharmacogenetic mechanisms in epilepsy; Drug target alterations; Drug related mechanisms of drug resistance in epilepsy; Tolerance and drug resistance mechanisms

Indexed keywords

EID: 84878366681     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444316667.ch8     Document Type: Chapter

References (92)

1. Schmidt D, Löscher W. Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia 2005; 46: 858-877.
2. Picot MC, Baldy-Moulinier M, Daures JP, Dujols P, Crespel A. The prevalence of epilepsy and pharmacoresistant epilepsy in adults: A population-based study in a Western European country. Epilepsia 2008; 49:1230-1238.
3. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000; 342: 314-319.
4. Schiller Y, Najjar Y. Quantifying the response to antiepileptic drugs:effect of past treatment history. Neurology 2008; 70: 54-65.
5. Tellez-Zenteno JF, Dhar R, Wiebe S. Long-term seizure outcomes following epilepsy surgery: a systematic review and meta-analysis. Brain 2005; 128: 1188-1198.
6. Elger CE, Schmidt D. Modern management of epilepsy: a practical approach. Epilepsy Behav 2008; 12: 501-539.
7. Regesta G, Tanganelli P. Clinical aspects and biological bases of drugresistant epilepsies. Epilepsy Res 1999; 34: 109-122.
8. Berg AT, Lin J, Ebrahimi N, Testa FM, Levy SR, Shinnar S. Modeling remission and relapse in pediatric epilepsy: application of a Markov process. Epilepsy Res 2004; 60: 31-40.
9. Spooner CG, Berkovic SF, Mitchell LA, Wrennall JA, Harvey AS. Newonset temporal lobe epilepsy in children: lesion on MRI predicts poor seizure outcome. Neurology 2006; 67: 2147-2153.
10. Sillanpää M, Schmidt D. Natural history of treated childhood-onset epilepsy: prospective, long-term population-based study. Brain 2006; 129: 617-624.
11. Sillanpää M, Schmidt D. Seizure clustering during drug treatment affects seizure outcome and mortality of childhood-onset epilepsy. Brain 2008; 131: 938-944.
12. Engel J Jr, Wiebe S, French J, et al. Practice parameter: temporal lobe and localized neocortical resections for epilepsy: report of the Quality Standards Subcommittee of the American Academy of Neurology, in association with the American Epilepsy Society and the American Association of Neurological Surgeons. Neurology 2003; 60: 538-547.
13. Tellez-Zenteno JF, Dhar R, Hernandez-Ronquillo L, Wiebe S. Long-term outcomes in epilepsy surgery: antiepileptic drugs, mortality, cognitive and psychosocial aspects. Brain 2007; 130: 334-345.
14. Schmidt D, Löscher W. How effective is surgery to cure seizures in drugresistant temporal lobe epilepsy? Epilepsy Res 2003; 56: 85-91.
15. Chapell R, Reston J, Snyder D, Treadwell J, Treager S, Turkelson C. Management of treatment-resistant epilepsy. Evid Rep Technol Assess (Summ) 2003; 1-8.
16. Schramm J. Temporal lobe epilepsy surgery and the quest for optimal extent of resection: a review. Epilepsia 2008; 49: 1296-1307.
17. Schmidt D. How many patients with drug-resistant epilepsy become seizure free because of surgery? In: Kahane P, Berg A, Löscher W, Nordli D, Perucca E (eds). Drug-Resistant Epilepsies. Esher, UK: John Libbey EuroText, 2008: 141-152.
18. Wiebe S, Blume WT, Girvin JP, Eliasziw M. A randomized, controlled trial of surgery for temporal-lobe epilepsy. N Engl J Med 2001; 345: 311-318.
19. Bien CG, Schulze-Bonhage A, Soeder BM, Schramm J, Elger CE, Tiemeier H. Assessment of the long-term effects of epilepsy surgery with three different reference groups. Epilepsia 2006; 47: 1865-1869.
20. Selwa LM, Schmidt SL, Malow BA, Beydoun A. Long-term outcome of nonsurgical candidates with medically refractory localization-related epilepsy. Epilepsia 2003; 44: 1568-1572.
21. Callaghan BC, Anand K, Hesdorffer D, Hauser WA, French JA. Likelihood of seizure remission in an adult population with refractory epilepsy. Ann Neurol 2007; 62: 382-389.
22. Luciano AL, Shorvon SD. Results of treatment changes in patients with apparently drug-resistant chronic epilepsy. Ann Neurol 2007; 62:375-381.
23. Cendes F, Andermann F, Dubeau F, Matthews PM, Arnold DL. Normalization of neuronal metabolic dysfunction after surgery for temporal lobe epilepsy. Evidence from proton MR spectroscopic imaging. Neurology 1997; 49: 1525-1533.
24. Dupont S, Croize AC, Semah F, et al. Is amygdalohippocampectomy really selective in medial temporal lobe epilepsy? A study using positron emission tomography with (18)fluorodeoxyglucose. Epilepsia 2001; 42:731-740.
25. Läppchen CH, Feil B, Fauser S, Wuwer Y, Glocker FX, Schulze-Bonhage A. Changes in intracortical excitability after successful epilepsy surgery. Epilepsy Res 2008; 79: 55-62.
26. Kelley K, Theodore WH. Prognosis 30 years after temporal lobectomy. Neurology 2005; 64: 1974-1976.
27. Jutila L, Immonen A, Mervaala E, et al. Long term outcome of temporal lobe epilepsy surgery: analyses of 140 consecutive patients. J Neurol Neurosurg Psychiatry 2002; 73: 486-494.
28. Sperling MR, Nei M, Zangaladze A, et al. Prognosis after late relapse following epilepsy surgery. Epilepsy Res 2008; 78: 77-81.
29. Schmidt D, Baumgartner C, Löscher W. Seizure recurrence after planned discontinuation of antiepileptic drugs in seizure free patients after epilepsy surgery: a review of current clinical experience. Epilepsia 2004; 45:179-186.
30. Morimoto K, Fahnestock M, Racine RJ. Kindling and status epilepticus models of epilepsy: rewiring the brain. Prog Neurobiol 2004; 73:1-60.
31. Nadler JV. The recurrent mossy fiber pathway of the epileptic brain. Neurochem Res 2003; 28: 1649-1658.
32. Sloviter RS. Status epilepticus-induced neuronal injury and network reorganization. Epilepsia 1999; 40: S34-S39.
33. Volk HA, Arabadzisz D, Fritschy JM, Brandt C, Bethman K, Löscher W. Antiepileptic drug resistant rats differ from drug responsive rats in hippocampal neurodegeneration and GABAA-receptor ligand-binding in a model of temporal lobe epilepsy. Neurobiol Dis 2006; 21: 633-646.
34. Bethmann K, Fritschy JM, Brandt C, Löscher W. Antiepileptic drug resistant rats differ from drug responsive rats in GABA A receptor subunit expression in a model of temporal lobe epilepsy. Neurobiol Dis 2008; 31; 169-187.
35. Remy S, Beck H. Molecular and cellular mechanisms of pharmacoresistance in epilepsy. Brain 2006; 129: 18-35.
36. Rogawski MA, Löscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci 2004; 5: 553-564.
37. Vreugdenhil M, Vanveelen CWM, Vanrijen PC, Dasilva FHL, Wadman WJ. Effect of valproic acid on sodium currents in cortical neurons from patients with pharmaco-resistant temporal lobe epilepsy. Epilepsy Res 1998; 32: 309-320.
38. Remy S, Gabriel S, Urban BW, et al. A novel mechanism underlying drug resistance in chronic epilepsy. Ann Neurol 2003; 53: 469-479.
39. Remy S, Urban BW, Elger CE, Beck H. Anticonvulsant pharmacology of voltage-gated Na+ channels in hippocampal neurons of control and chronically epileptic rats. Eur J Neurosci 2003; 17: 2648-2658.
40. Schaub C, Uebachs M, Beck H. Diminished response of CA1 neurons to antiepileptic drugs in chronic epilepsy. Epilepsia 2007; 48: 1339-1350.
41. Ellerkmann RK, Remy S, Chen J, et al. Molecular and functional changes in voltage-dependent Na(+) channels following pilocarpine-induced status epilepticus in rat dentate granule cells. Neuroscience 2003; 119:323-333.
42. Lucas PT, Meadows LS, Nicholls J, Ragsdale DS. An epilepsy mutation in the beta1 subunit of the voltage-gated sodium channel results in reduced channel sensitivity to phenytoin. Epilepsy Res 2005; 64:77-84.
43. Jandova K, Pasler D, Antonio LL, et al. Carbamazepine-resistance in the epileptic dentate gyrus of human hippocampal slices. Brain 2006; 129:3290-3306.
44. Jeub M, Beck H, Siep E, et al. Effect of phenytoin on sodium and calcium currents in hippocampal CA1 neurons of phenytoin-resistant kindled rats. Neuropharmacology 2002; 42: 107-16.
45. Brooks-Kayal AR, Shumate MD, Jin H, Rikhter TY, Coulter DA. Selective changes in single cell GABAA receptor subunit expression and function in temporal lobe epilepsy. Nature Medicine 1998; 4: 1166-1172.
46. Coulter DA. Mossy fiber zinc and temporal lobe epilepsy: pathological association with altered 'epileptic' gamma-aminobutyric acid A receptors in dentate granule cells. Epilepsia 2000; 41(Suppl. 6): S96-S99.
47. Coulter DA. Epilepsy-associated plasticity in gamma-aminobutyric acid receptor expression, function, and inhibitory synaptic properties. Int Rev Neurobiol 2001; 45: 237-252.
48. Cohen I, Navarro V, Clemenceau S, Baulac M, Miles R. On the origin of interictal activity in human temporal lobe epilepsy in vitro. Science 2002; 298: 1418-1421.
49. Loup F, Wieser HG, Yonekawa Y, Aguzzi A, Fritschy JM. Selective alterations in GABAA receptor subtypes in human temporal lobe epilepsy. J Neurosci 2000; 20: 5401-5419.
50. Jones DM, Esmaeil N, Maren S, Macdonald RL. Characterization of pharmacoresistance to benzodiazepines in the rat Li-pilocarpine model of status epilepticus. Epilepsy Res 2002; 50: 301-312.
51. Chen JW, Wasterlain CG. Status epilepticus: pathophysiology and management in adults. Lancet Neurol 2006; 5: 246-256.
52. Goodkin HP, Yeh JL, Kapur J. Status epilepticus increases the intracellular accumulation of GABAA receptors. J Neurosci 2005; 25:5511-5520.
53. Naylor DE, Liu H, Wasterlain CG. Trafficking of GABA(A) receptors, loss of inhibition, and a mechanism for pharmacoresistance in status epilepticus. J Neurosci 2005; 25: 7724-7733.
54. Ben Ari Y, Holmes GL. The multiple facets of gamma-aminobutyric acid dysfunction in epilepsy. Curr Opin Neurol 2005; 18: 141-145.
55. Cohen AS, Lin DD, Quirk GL, Coulter DA. Dentate granule cell GABA(A) receptors in epileptic hippocampus: enhanced synaptic efficacy and altered pharmacology. Eur J Neurosci 2003; 17: 1607-1616.
56. Rivera C, Voipio J, Kaila K. Two developmental switches in GABAergic signalling: the K+-Cl-cotransporter KCC2 and carbonic anhydrase CAVII. J Physiol 2005; 562: 27-36.
57. Löscher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 2005; 6: 591-602.
58. Löscher W, Potschka H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol 2005; 76: 22-76.
59. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 2003; 55: 3-29.
60. Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. Oncologist 2003; 8: 411-424.
61. Fromm MF. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 2004; 25: 423-429.
62. Begley DJ. ABC transporters and the blood-brain barrier. Curr Pharm Des 2004; 5410: 1295-1312.
63. Tishler DM, Weinberg KT, Hinton DR, Barbaro N, Annett GM, Raffel C. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 1995; 36: 1-6.
64. Kwan P, Brodie MJ. Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsia 2005; 46: 224-235.
65. Oby E, Janigro D. The blood-brain barrier and epilepsy. Epilepsia 2006; 47: 1761-1774.
66. Sisodiya SM, Lin W-R, Harding BN, Squier MV, Keir G, Thom M. Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain 2002; 125: 22-31.
67. Sisodiya SM, Heffernan J, Squier MV. Over-expression of P-glycoprotein in malformations of cortical development. Neuroreport 1999; 10:3437-3441.
68. Lazarowski A, Czornyj L, Lubienieki F, Girardi E, Vazquez S, D'Giano C. ABC transporters during epilepsy and mechanisms underlying multidrug resistance in refractory epilepsy. Epilepsia 2007; 48(Suppl. 5):140-149.
69. Schinkel AH, Wagenaar E, Mol CA, van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996; 97: 2517-2524.
70. Rizzi M, Caccia S, Guiso G, et al. Limbic seizures induce P-glycoprotein in rodent brain: functional implications for pharmacoresistance. J Neurosci 2002; 22: 5833-9.
71. Sills GJ, Kwan P, Butler E, de Lange EC, van den Berg DJ, Brodie MJ. P-glycoprotein-mediated efflux of antiepileptic drugs: preliminary studies in mdr1a knockout mice. Epilepsy Behav 2002; 3: 427-432.
72. Baltes S, Gastens AM, Fedrowitz M, Potschka H, Kaever V, Löscher W. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology 2007; 52: 333-346.
73. Luna Tortos C, Fedrowitz M, Löscher W. Several major antiepileptic drugs are substrates for human P-glycoprotein. Epilepsia 2007; 48(Suppl. 6): 365.
74. Cucullo L, Hossain M, Rapp E, Manders T, Marchi N, Janigro D. Development of a humanized in vitro blood-brain barrier model to screen for brain penetration of antiepileptic drugs. Epilepsia 2007; 48:505-516.
75. van Vliet EA, van Schaik R, Edelbroek PM, et al. Region-specific overexpression of P-glycoprotein at the blood-brain barrier affects brain uptake of phenytoin in epileptic rats. J Pharmacol Exp Ther 2007; 322:141-147.
76. Marchi N, Guiso G, Rizzi M, et al. A pilot study on brain-to-plasma partition of 10,11-dyhydro-10-hydroxy-5H-dibenzo(b,f)azepine-5-carboxamide and MDR1 brain expression in epilepsy patients not responding to oxcarbazepine. Epilepsia 2005; 46: 1613-1619.
77. Potschka H, Löscher W. A comparison of extracellular levels of phenytoin in amygdala and hippocampus of kindled and non-kindled rats. Neuroreport 2002; 13: 167-171.
78. Volk HA, Löscher W. Multidrug resistance in epilepsy: rats with drugresistant seizures exhibit enhanced brain expression of P-glycoprotein compared with rats with drug-responsive seizures. Brain 2005; 128:1358-1368.
79. Löscher W. Animal models of drug-resistant epilepsy. Novartis Found Symp 2002; 243: 149-159; discussion 159-166.
80. Löscher W, Potschka H. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J Pharmacol Exp Ther 2002; 301:7-14.
81. Potschka H, Baltes S, Löscher W. Inhibition of multidrug transporters by verapamil or probenecid does not alter blood-brain barrier penetration of levetiracetam in rats. Epilepsy Res 2004; 58: 85-91.
82. Brandt C, Bethmann K, Gastens AM, Löscher W. The multidrug transporter hypothesis of drug resistance in epilepsy: proof-of-principle in a rat model of temporal lobe epilepsy. Neurobiol Dis 2006; 24:202-211.
83. Summers MA, Moore JL, McAuley JW. Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy. Ann Pharmacother 2004; 38: 1631-1634.
84. Iannetti P, Spalice A, Parisi P. Calcium-channel blocker verapamil administration in prolonged and refractory status epilepticus. Epilepsia 2005; 46: 967-969.
85. Löscher W, Schmidt D. Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs. Epilepsia 2006; 47: 1253-1284.
86. Löscher W, Klotz U, Zimprich F, Schmidt D. The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia 2009; 50: 1-23.
87. Depondt C. The potential of pharmacogenetics in the treatment of epilepsy. Eur J Paediatr Neurol 2006; 10: 57-65.
88. Tate SK, Depondt C, Sisodiya SM, et al. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc Natl Acad Sci USA 2005; 102: 5507-5512.
89. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 3473-3478.
90. Siddiqui A, Kerb R, Weale ME, et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 2003; 348: 1442-1448.
91. Ebid AH, Ahmed MM, Mohammed SA. Therapeutic drug monitoring and clinical outcomes in epileptic Egyptian patients: a gene polymorphism perspective study. Ther Drug Monit 2007; 29: 305-312.
92. Basic S, Hajnsek S, Bozina N, et al. The influence of C3435T polymorphism of ABCB1 gene on penetration of phenobarbital across bloodbrain barrier in patients with generalized epilepsy. Seizure 2008; 17:524-530.